Efsubaglutide Alfa
ApprovedPeptide
Efsubaglutide Alfa is one of 57 biologic programs targeting Type 2 Diabetes. It is currently in Approved.
2
Indications
5
Total Trials
3
Active Trials
56
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
885 competitors in Type 2 Diabetes
#DrugCompanyPhaseTrials
1Efsubaglutide Alfa
SShanghai Yinnuo Pharmaceutical Technology Co., Ltd.
Approved
Cysteine Hydrochloride
NovartisPreclinical
Aurlumyn
BBTG International Inc.
Preclinical
Sulfonylureas
Eli LillyPreclinical
SGLT-2 Inhibitor
SSheffield Teaching Hospitals NHS Foundation Trust
Preclinical
Blank Control
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Preclinical
Henagliflozin
TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Preclinical
Dipeptidyl Peptidase-4 Inhibitors
Boehringer IngelheimPreclinical
Sglt2i
UUniversity of Chicago
Preclinical
Glucagon-Like Peptide-1 (GLP-1)
Novo NordiskPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Overweight2 trials
Efficacy and Safety1 trial
Efficacy and Safety of Efsubaglutide Alfa Injection 3 Mg Q2W in T2D Patients
Not yet recruiting·SShanghai Yinnuo Pharmaceutical Technology Co., Ltd.·Phase 3·NCT06900075·88 enrolled
Type 2 Diabetes1 trial
Obesity1 trial
Evaluating Anti-Obesity Medications 6 Months After Metabolic Surgery
Recruiting·TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School·Phase 4·NCT07163650·60 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Efsubaglutide Alfa. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details